brigatinib
Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. It is a small molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.. Reference standards of Brigatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
stdClass Object
(
[pname] => Brigatinib
[catalogue_number] => PA 29 44000
[category_ids] => ,78,72,80,79,
[chemical_name] =>
[weight] => 584.09
[form] => C29H39ClN7O2P
[cas] => 1197953-54-0
[pslug] => 1197953-54-0-brigatinib-api-pa2944000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 29 44000
Molecular Formula : C29H39ClN7O2P
Molecular Weight : 584.09
stdClass Object
(
[pname] => 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl]
[catalogue_number] => PA 29 0441000
[category_ids] => ,171,78,72,80,79,
[chemical_name] =>
[weight] => 570.07
[form] => C28H37ClN7O2P
[cas] => 1197958-75-0
[pslug] => 1197958-75-0-2-4-pyrimidinediamine-5-chloro-n4-2-dimethylphosphinyl-phenyl-n2-2-methoxy-4-4-1-piperazinyl-1-piperidinyl-phenyl-pa290441000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl]
Catalogue No.:PA 29 0441000
Molecular Formula : C28H37ClN7O2P
Molecular Weight : 570.07
